The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury

Background: To evaluate the efficacy and side-effects of cyclosporine-A (CsA) in improvement of consciousness and cognitive dysfunction of patients with diffuse axonal injury (DAI) after traumatic brain injury (TBI). Materials and Methods: This study is designed as a randomized double-blind placeb...

Full description

Bibliographic Details
Main Authors: Bahram Aminmansour, Salman Abbasi Fard, Majid Rezvani Habibabadi, Payam Moein, Rasoul Norouzi, Morteza Naderan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-01-01
Series:Advanced Biomedical Research
Subjects:
Online Access:http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=35;epage=35;aulast=Aminmansour
id doaj-a8f5634b95f74fff81087ee82c66bc6b
record_format Article
spelling doaj-a8f5634b95f74fff81087ee82c66bc6b2020-11-25T00:42:26ZengWolters Kluwer Medknow PublicationsAdvanced Biomedical Research2277-91752277-91752014-01-0131353510.4103/2277-9175.125031The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injuryBahram AminmansourSalman Abbasi FardMajid Rezvani HabibabadiPayam MoeinRasoul NorouziMorteza NaderanBackground: To evaluate the efficacy and side-effects of cyclosporine-A (CsA) in improvement of consciousness and cognitive dysfunction of patients with diffuse axonal injury (DAI) after traumatic brain injury (TBI). Materials and Methods: This study is designed as a randomized double-blind placebo-controlled with 100 patients suffered from DAI. CsA was administered to the intervention group (n = 50) as 5 mg/kg/24 h via 250 ml dextrose water (DW) 5% solution (DW 5%) during the first 8 h after trauma. The control group (n = 50) received only DW 5% in the same course. The presenting Glasgow coma scale in addition to the Glasgow outcome scale-extended (GOS-E) and mini-mental state examination (MMSE) in the 3 rd and 6 th months after trauma were documented. The serum values for complete blood count (CBC), blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were checked to assess for complications. Results: Most patients in both groups had type II DAI (46%). There was no significant difference between groups in the GOS-E scores after 3 and 6 months. All participants were in moderate or severe classes of MMSE with no statistically significant difference. Except for the higher BUN level in the cyclosporine treated group, 48 h after admission (P = 0.012), the difference in the level of Cr, AST, ALT, and ALP was not significant and all were in the normal range. The CBC results showed only significant difference for White Blood Cell (WBC) count at 12 h (P = 0.000). Conclusion: The administration of CsA is not effective in the improvement of consciousness and cognitive function. However, it brings about no adverse effects.http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=35;epage=35;aulast=AminmansourCyclosporine-adiffuse axonal injuryneuroprotectionneurorecoverytraumatic brain injury
collection DOAJ
language English
format Article
sources DOAJ
author Bahram Aminmansour
Salman Abbasi Fard
Majid Rezvani Habibabadi
Payam Moein
Rasoul Norouzi
Morteza Naderan
spellingShingle Bahram Aminmansour
Salman Abbasi Fard
Majid Rezvani Habibabadi
Payam Moein
Rasoul Norouzi
Morteza Naderan
The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury
Advanced Biomedical Research
Cyclosporine-a
diffuse axonal injury
neuroprotection
neurorecovery
traumatic brain injury
author_facet Bahram Aminmansour
Salman Abbasi Fard
Majid Rezvani Habibabadi
Payam Moein
Rasoul Norouzi
Morteza Naderan
author_sort Bahram Aminmansour
title The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury
title_short The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury
title_full The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury
title_fullStr The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury
title_full_unstemmed The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury
title_sort efficacy of cyclosporine-a on diffuse axonal injury after traumatic brain injury
publisher Wolters Kluwer Medknow Publications
series Advanced Biomedical Research
issn 2277-9175
2277-9175
publishDate 2014-01-01
description Background: To evaluate the efficacy and side-effects of cyclosporine-A (CsA) in improvement of consciousness and cognitive dysfunction of patients with diffuse axonal injury (DAI) after traumatic brain injury (TBI). Materials and Methods: This study is designed as a randomized double-blind placebo-controlled with 100 patients suffered from DAI. CsA was administered to the intervention group (n = 50) as 5 mg/kg/24 h via 250 ml dextrose water (DW) 5% solution (DW 5%) during the first 8 h after trauma. The control group (n = 50) received only DW 5% in the same course. The presenting Glasgow coma scale in addition to the Glasgow outcome scale-extended (GOS-E) and mini-mental state examination (MMSE) in the 3 rd and 6 th months after trauma were documented. The serum values for complete blood count (CBC), blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were checked to assess for complications. Results: Most patients in both groups had type II DAI (46%). There was no significant difference between groups in the GOS-E scores after 3 and 6 months. All participants were in moderate or severe classes of MMSE with no statistically significant difference. Except for the higher BUN level in the cyclosporine treated group, 48 h after admission (P = 0.012), the difference in the level of Cr, AST, ALT, and ALP was not significant and all were in the normal range. The CBC results showed only significant difference for White Blood Cell (WBC) count at 12 h (P = 0.000). Conclusion: The administration of CsA is not effective in the improvement of consciousness and cognitive function. However, it brings about no adverse effects.
topic Cyclosporine-a
diffuse axonal injury
neuroprotection
neurorecovery
traumatic brain injury
url http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=35;epage=35;aulast=Aminmansour
work_keys_str_mv AT bahramaminmansour theefficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT salmanabbasifard theefficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT majidrezvanihabibabadi theefficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT payammoein theefficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT rasoulnorouzi theefficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT mortezanaderan theefficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT bahramaminmansour efficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT salmanabbasifard efficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT majidrezvanihabibabadi efficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT payammoein efficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT rasoulnorouzi efficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
AT mortezanaderan efficacyofcyclosporineaondiffuseaxonalinjuryaftertraumaticbraininjury
_version_ 1725282579085524992